Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Financial Select Sector SPDR Fund — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Financial Select Sector SPDR Fund trades at $54.64 (market cap $52.24B). The key difference: Financial Select Sector SPDR Fund is far larger — about 6.9× Spyre Therapeutics Inc. Common Stock's market cap, and Financial Select Sector SPDR Fund is more actively traded (44,490,388 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Financial Select Sector SPDR Fund for 104 Days on average.
| SYRE | XLF | |
|---|---|---|
Market Cap | $7.52B | $52.24B |
Volume | 1,441,031 | 44,490,388 |
Sector | Health | — |
52-Week High | $108.92 | $58.55 |
52-Week Low | $22.18 | $47.80 |
Typical Hold Time | 0 Days | 104 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XLF trades at $54.82, down 0.42% amid mixed technical signals with a bullish moving average trend but neutral oscillators. The ETF faces sector headwinds as financial stocks lag the broader market despite rising bank profits. Recent Federal Reserve stress test changes and interest rate hikes create both opportunities and challenges for financial sector performance.
The financial sector ETF shows potential for benefiting from rising interest rates, though regulatory uncertainty and market underperformance relative to the S&P 500 present near-term risks. Institutional rotation into financials in Q2 2026 suggests confidence in the sector's rate sensitivity advantages over technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
